ABSTRACT

Over the past few decades physicians and scientists have been trying to reduce the burden of childhood pneumonia still it accounts for 15% among all under 5 year old child deaths, even in 2015. Haemophilus influenzae is an important pathogen in causing childhood pneumonia and other respiratory disease children. Due to introduction of Hin conjugate vaccine the Hib prevalence is near to zero. Latest report evidences non-Hib and non-typeable (in 70-80% cases) strains becoming more invasive. This study was designed to find out if Haemophilus influenzae present among the pneumonic patients and remain associated with some clinicoepidemiological factors with serotype specific confirmation and if Hin strains differ in bacteriological, biochemical and serological characteristics. With prior consent, nasopharyngeal swabs (NPS) were taken from 260 children under-5 years-old, of them 83% were pneumonic or partially treated for pneumonia, 56% males and 44% females who received antibiotic in ≤ 3 doses. NPS-samples transported (in Brain heart infusion-broth) to AIMSTlaboratory (within 3-4 hours) were cultured in Chocolate-II Agar in presence of 5% CO2 at 35-37°C. Colony morphology were observed (pleomorphic, small-to-medium pale greyish colonies), microscopically verified (pinkish gram negative cocobacilli) and serologically confirmed and antimicrobial susceptibility testing was performed using n=10 antibiotic-discs where oxacillin and penicillin-G were nearly 100% resistant but 3rd generation cefalexin group were 100% sensitive to Haemophilus influenzae. Hin isolates were confirmed by employing PCR using two specific primers and found that, all the 13 phenotypically identified are nontypeable. Clinical findings (diagnosed by pediatricians) revealed n=220, 83% pneumonia & bronchopneumonia (including partially-treated) and 17% ALRI and our lab results determined the 5% were Hin (n=13 of 260) in those CPn-cases that we studied from two hospitals of Kedah. Non-typeable Hin-strains that we found also remain similar to other reports posing an important question if we need a new vaccine, in-addition with the currently available Hib vaccine. This keeps our door open to conduct further clinico-epidemiological and molecular studies to clear the pathogenicity of non-typeable Haemophilus influenzae.